Business, energy, technology, markets and global industry news from Business News Today

LEO Pharma

PharmaDeviceNews LEO Pharma
LEO Pharma’s TRAPEDS-1 trial evaluated the pharmacokinetics and long-term safety of tralokinumab in children with moderate-to-severe atopic dermatitis. Representative image.
Pharma & Biotech

LEO Pharma reports long-term pediatric tralokinumab safety findings from TRAPEDS-1

LEO Pharma’s TRAPEDS-1 data support pediatric tralokinumab development, but the small trial leaves efficacy and approval questions open.

Read More
Representative image: A dermatologist examines chronic hand eczema as LEO Pharma’s ESCD 2026 data highlight the condition’s impact on work, school participation and daily life.
Pharma & Biotech

Why LEO Pharma is shifting the chronic hand eczema debate from skin clearance to life impact

New analyses from the DELTA FORCE and DELTA TEEN programmes extend the chronic hand eczema discussion beyond skin clearance. The findings could strengthen the clinical and economic case for delgocitinib, although real-world effectiveness, adolescent regulation and treatment access remain important tests.

Read More
Representative image of topical plaque psoriasis treatment and China market expansion, illustrating LEO Pharma’s Enstilar approval as the company targets growth in the world’s largest psoriasis patient market.
Pharma & Biotech

LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?

LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.

Read More